Skip to Content

New CLL Study Supports Inclusion of Venetoclax Plus Obinutuzumab in Treatment Guidelines

Listen to Dr. Othman Al-Sawaf from University of Cologne, explaining why he believes that venetoclax plus obinutuzumab should have a prominent position in the treatment guidelines for CLL, in both elderly and younger patients, as well as fit and unfit patients. Dr. Al-Sawaf’s perspective is based on the compelling data from the CLL14 study, which was highlighted as one of the seven particularly noteworthy abstracts at EHA23.

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top